Please assess the completion status of the following clinical trial:

Trial Title: Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criterion for follow-on subjects:~* Individuals who participated to Study V72_41 or V72P10 and have completed vaccination with rMenB+OMV NZ according to a 2-dose schedule~Inclusion Criterion for naïve subjects:~* Individuals of 15 through 21 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72_41.~* 17 through 24 years of age on the day of informed consent and assent as applicable (according to the subject's age) for subjects enrolled at sites that participated to Study V72P10.~Inclusion Criteria for all subjects:~* Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.~* Individuals who can comply with study procedures including follow-up.~* Males Or Females of non-childbearing potential Or Females of childbearing potential who are using an effective birth control method .~Exclusion Criteria for all subjects~Exclusion Criterion for follow-on subjects:~• Received a third dose of a Meningococcal group B vaccine prior to enrolment in this study.~Exclusion Criterion for naïve subjects:~• Received any other Meningococcal group B vaccines prior to enrolment in this study.~Exclusion Criteria for all subjects:~* Progressive, unstable or uncontrolled clinical conditions.~* Hypersensitivity, including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study.~* Abnormal function of the immune system.~* Received immunoglobulins or any blood products within 180 days prior to informed consent and assent as applicable (according to the subject's age).~* Received an investigational or non-registered medicinal product within 30 days prior to informed consent and assent as applicable (according to the subject's age).~* Study personnel as an immediate family or household member.~* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.~* Positive results at the urine pregnancy test performed before study vaccination.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- Group 3B (Type: EXPERIMENTAL): Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
- Group B_0_1 (Type: ACTIVE_COMPARATOR): Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete